0:25
In this concise explanation, the presenter outlines why users of retatrutide—or any GLP‑1 agonist such as semaglutide or tirzepatide—may experience fatigue, headaches, muscle cramps, and a general sense of malaise during weight‑loss. The core mechanism described is that GLP‑1‑driven weight loss reduces circulating insulin; because insulin promotes sodium retention, its decline causes the body to lose sodium and other electrolytes. The resulting electrolyte depletion is identified as the physiological basis for the listed side‑effects.
